Influencer claims, fact-checked.
Common objections to the peptide field, lined up against what the published evidence actually shows. Each response surfaces the part the critic gets right alongside the part that does not survive contact with the underlying literature.
- Responses live
- 39
- Peptide-anchored
- 8
- Field-wide
- 31
01·Field-wide objection
AI-translated research papers aren't trustworthy — you can't rely on a machine translation of medical literature.
The objection treats 'AI translation' as a single thing, but the actual question is about provenance discipline and editorial QC, not about which language tool produced the first draft. A well-flagged AI-extraction with verified numerics, explicit confidence notes, and acknowledged paywall gaps is more transparent than a human-translated summary that hides its working.
Read the full response
02·Field-wide objection
AOD-9604 is a proven fat-loss peptide that retains hGH's lipolytic effect without its diabetogenic side effects.
AOD-9604's Phase 2b trial (n=536, 2007) missed its primary weight-loss endpoint and Metabolic Pharmaceuticals' obesity development program effectively ended. The molecule has GRAS food/supplement safety determination but no controlled-trial efficacy data. The marketing narrative rests on preclinical lipolysis mechanism, not pivotal-trial outcomes.
Read the full response
03·Field-wide objection
BPC-157 is safe because it comes from a natural body protein. It's a fragment of human gastric juice protein, so it can't really be foreign to the body.
BPC-157 was identified from a screen of synthetic peptides modeled on a putative human gastric-juice protein fragment, but the molecule that exists in vials is a fully synthetic peptide whose safety in humans is not established by its naming origin or its rat-model literature; the 'natural' framing is etymological history, not a safety claim.
Read the full response
04·On BPC-157
BPC-157 will give you cancer because it's pro-angiogenic
Pro-angiogenic activity in rodent models is real, but the cancer-risk leap conflates mechanism with clinical outcome — there is no human evidence that BPC-157 administration causes or accelerates cancer, and the entire BPC-157 human safety record is small enough that a population signal could not yet be detected either way.
Read the full response
05·Field-wide objection
Chronic peptide injection causes anti-drug antibody development that makes peptides lose effect over time. That's why you have to cycle off — the body builds resistance.
Anti-drug antibody development is a real and documented phenomenon for some peptide therapeutics — primarily large recombinant proteins and modified peptides with non-native sequence — but it does not explain most cases of perceived peptide tolerance, which instead reflect receptor desensitization, downstream regulatory compensation, or placebo wash-out.
Read the full response
06·Field-wide objection
Compounded peptides are unsafe
Sourcing quality is real and consequential, and the gap between regulatory-grade pharmacy compounding and unregulated 'research chemical' supply is wider than most readers realize — but the objection collapses the two and treats every non-branded peptide as equivalent risk.
Read the full response
07·Field-wide objection
Compounded semaglutide is the same as Ozempic / Wegovy. Same molecule, same effect, just cheaper.
Compounded semaglutide products are not regulated as therapeutic equivalents of branded Wegovy or Ozempic. They use different salt forms (acetate, citrate), are not required to demonstrate the same purity, sterility, or batch-to-batch consistency, and the FDA's drug-shortage rationale that legally enabled their compounding ended in 2024-2025 — though enforcement and gray-market continuation are ongoing as of 2026.
Read the full response
08·On Dihexa
Dihexa is 10 million times more potent than BDNF for promoting synaptogenesis — the most powerful nootropic ever developed.
The '10 million times more potent than BDNF' figure refers to a single cell-culture synaptogenesis assay in the now-Expression-of-Concern McCoy 2013 paper. It does not mean Dihexa is 10 million times more cognitively potent in humans — there are no published human Dihexa trials. The marketing-friendly comparison has propagated far beyond what the original methodology supports.
Read the full response
09·On Epitalon
Epitalon activates telomerase, which lengthens telomeres, which means it reverses cellular aging.
Each step in that chain has real evidence but the final conclusion overstates what the evidence supports. Telomerase activity in vitro is documented (small-scale, in cultured cells). Telomere length effects in vivo in humans are not characterized. The causal chain from telomere length to functional aging is itself contested in modern geroscience.
Read the full response
10·Field-wide objection
Epitalon, MOTS-c, SS-31, and the broader anti-aging peptide stack have been shown to extend lifespan and slow aging in humans. The biohacker longevity community is the leading edge of life-extension medicine.
No peptide has been shown to extend human lifespan in a controlled trial. Surrogate-biomarker shifts and animal-model lifespan data are real but do not establish human longevity benefit; the rigorous human-aging trial body for any peptide is essentially zero, and the burden of proof remains with the longevity-extension claim.
Read the full response
11·Field-wide objection
FDA-approved peptide drugs are just patent-extending pharma plays without meaningful clinical advance
The patent-extension critique applies to some peptide approvals and not to others; treating the class as uniformly evergreened ignores that several recent peptide approvals (SELECT semaglutide, SURMOUNT-OSA tirzepatide, NETTER-1 PRRT, teriparatide's post-marketing safety re-grading) represent genuinely novel pharmacology with FDA-approved label expansion based on randomized-trial outcome data.
Read the full response
12·Field-wide objection
GLP-1 receptor agonists cause pancreatic cancer. The FAERS database is flooded with pancreatitis and pancreatic cancer reports — these drugs are giving people cancer.
The early pharmacovigilance signal from Singh 2013 has been reanalyzed; large RCT meta-analyses and registry studies subsequent to 2015 have not found increased pancreatic cancer risk in GLP-1 RA users. The persistent claim that 'GLP-1s cause pancreatic cancer' is not supported by the controlled-trial evidence base built over the decade after the initial concern.
Read the full response
13·Field-wide objection
Generic semaglutide will hit the US market by 2027 and tirzepatide shortly after. Costs will drop 90%, the compounding problem will resolve, and the GLP-1 access question will be over.
The earliest US semaglutide composition-of-matter patent expires December 2031 (not 2027), and the tirzepatide compound patent runs to January 2036; the generic pathway is the abbreviated new drug application (ANDA) under Hatch-Waxman rather than the biosimilar pathway, but synthetic-peptide generics still carry impurity-immunogenicity demonstration requirements that small-molecule generics avoid; historical price-drop trajectories for follow-on biologics and complex peptides have been 15-40% on launch rather than 90%; the shortage-driven compounding pathway closed in 2024-2025 ahead of any generic; and manufacturing-capacity rather than patent status was the proximate driver of the 2023-2024 access crisis.
Read the full response
14·Field-wide objection
Higher dose = faster / better results. If 250 mcg of BPC-157 works, 1 mg works four times faster. If 5 mg of tirzepatide loses fat, 15 mg loses three times as much.
Peptide dose-response curves are sigmoidal, not linear. Higher dose accelerates desensitization, β-arrestin recruitment, and adverse events — the actual effect ceiling for most peptides is reached well below the doses circulating in practitioner forums.
Read the full response
15·On Semaglutide
I'll just run a 12-week semaglutide cycle, hit my goal weight, stop, and keep the result with diet.
The trial data tests this scenario directly and shows it doesn't work for most adopters. The STEP-4 discontinuation extension showed ~⅔ of the weight loss returning within 48 weeks of stopping semaglutide despite continued lifestyle counseling. The cycle-and-keep framing isn't what the pharmacology produces.
Read the full response
16·Field-wide objection
If peptides worked, clinical practice guidelines would have included them
Guideline inclusion is necessary but not sufficient evidence of clinical utility — the typical evidence-to-practice translation lag is 3-7 years, peptides with strong RCT evidence (semaglutide cardiovascular outcomes, tirzepatide OSA, lanreotide GEP-NETs) are entering major guidelines in real time, and the absence of guideline inclusion for research-grade peptides reflects an indication-RCT gap rather than evidence of negative outcome.
Read the full response
17·On Ipamorelin
Ipamorelin is just steroids with extra steps
Anabolic steroids and Ipamorelin are pharmacologically distinct in three load-bearing ways — the hormone they raise, how it ages out, and what they do to the rest of the endocrine system — and conflating the two trades clarity for false equivalence.
Read the full response
18·Field-wide objection
It's all just placebo because the studies are so small
Sample size matters and small trials produce wider confidence intervals around the true effect, but the objection misunderstands what placebo-controlled means and applies a critique appropriate for a thin literature uniformly across a corpus that is not uniformly thin.
Read the full response
19·On MK-677
MK-677 (Ibutamoren) tolerance doesn't develop — the GHS-R1a doesn't downregulate, and the molecule can be dosed continuously for years without diminishing effect.
Sustained G-protein-coupled-receptor agonism produces β-arrestin-mediated downregulation as a general pharmacological principle, and the Nass 2008 2-year trial documented adaptive metabolic changes (fasting glucose elevation, insulin sensitivity decline, fluid retention) alongside sustained IGF-1. The 'no tolerance, run it forever' framing is inconsistent with both receptor biology and the longest controlled-exposure dataset in the literature.
Read the full response
20·Field-wide objection
Microdosing GLP-1s (semaglutide, tirzepatide) at sub-therapeutic doses is harmless and gives you a 'metabolic edge' without side effects.
Sub-therapeutic GLP-1 dosing produces the same kind of long-term effects as therapeutic dosing — just smaller — including the lean-mass signal, the gallbladder signal, vulnerability to gastroparesis, and the same post-discontinuation rebound when stopped. The difference is a smaller benefit, not the absence of cost.
Read the full response
21·Field-wide objection
Mounjaro/Zepbound and Wegovy/Ozempic are basically the same drug — they're all GLP-1 agonists. Tirzepatide just has slightly different chemistry but the same mechanism. The choice is just about cost.
Tirzepatide is a dual GIP / GLP-1 receptor agonist; semaglutide is a single GLP-1 receptor agonist. The two molecules engage different receptor populations, produce different downstream pharmacology, generate different magnitudes of weight loss and HbA1c reduction in head-to-head trials, and have meaningfully different side-effect profiles — they are not the same drug with different branding.
Read the full response
22·Field-wide objection
My peptide came with an HPLC purity certificate of analysis showing >99% purity. That's the gold standard for peptide quality. It's pharmaceutical grade.
HPLC purity is one analytical assay among many that pharmaceutical-grade manufacturing requires. A >99% purity certificate at a single quality-control time point tells the reader nothing about endotoxin levels, sequence identity, sterility, batch-to-batch consistency, container-closure integrity, microbial contamination, residual solvent levels, or stability over storage — all of which are independent measurements with their own potential failure modes.
Read the full response
23·Field-wide objection
Off-label peptide use is just freedom of medicine. The FDA is paternalistic; informed adults should be able to access any peptide they want. The regulatory state is the problem; the gray market is the solution.
Off-label prescribing by a clinician is legal medicine; gray-market peptide purchasing by patients without clinical oversight is not off-label use — it is unregulated drug acquisition that bypasses the quality, pharmacovigilance, and accountability infrastructure that makes off-label prescribing reasonably safe in the first place.
Read the full response
24·Field-wide objection
PEGylated peptides last forever in the body — they're essentially permanent. That's why you only need them weekly or monthly. There's no PK problem to worry about; just inject and forget.
PEGylation extends peptide half-life but does not eliminate clearance — commercial PEGylated peptides have characterized half-lives of days to weeks, not 'forever'; chronic PEG exposure raises real anti-PEG antibody risks, tissue-accumulation concerns, and clearance-kinetic questions that the 'set and forget' framing ignores.
Read the full response
25·Field-wide objection
Peptides are just chains of amino acids — they're basically supplements; how could they be unsafe?
Treating peptides as equivalent to amino-acid supplements collapses a critical distinction: bioactivity depends on sequence, structure, and receptor specificity, not on whether the molecule is 'natural.' A 6-residue regulatory peptide acting on a specific receptor system is a different pharmacological object from undifferentiated amino-acid intake.
Read the full response
26·Field-wide objection
Peptides are too specific in their mechanism to interact with prescription medications. Unlike small molecules that hit multiple targets, peptides bind narrowly and don't cause drug interactions.
Peptide narrow target specificity at the receptor level does not translate to absence of clinical drug interactions; downstream physiological cascades, metabolic enzyme effects, and shared organ systems create real interaction potential that has been documented for FDA-approved peptides and is plausible-but-uncharacterized for the gray-market peptide class.
Read the full response
27·Field-wide objection
Peptides have plasma half-lives too short for real clinical effects
Native peptides have minute-to-second plasma half-lives — engineered analogs with protease-resistant substitutions, cyclization, fatty-acid albumin binding, and PEGylation routinely extend that to days or weeks, which is why semaglutide is dosed weekly and leuprolide depot lasts months.
Read the full response
28·Field-wide objection
Peptides like semaglutide are cheaper through compounding pharmacies because they exploit a loophole — same drug, fraction of the price, the FDA just hasn't caught up yet.
The compounded-semaglutide story is more nuanced than 'loophole.' Compounding under section 503A is a defined regulatory pathway with specific rules; the 2023-2024 shortage-driven compounded GLP-1 market exists because FDA allowed it during shortage and is now winding it down as supply normalises. Calling it a loophole obscures both the legitimate regulatory framework and the real quality variance across compounders.
Read the full response
29·Field-wide objection
Peptides will mess with your hormones long-term
Long-term endocrine effects are a real concern for the GH-axis and metabolic peptide classes — IGF-1 elevation, GLP-1 receptor adaptation, glucagon-axis activation — but they are class-specific, not a property of 'peptides' as a category, and the long-term human data exists for some peptides on this list and is genuinely absent for others.
Read the full response
30·Field-wide objection
Research-only peptides are safer than prescription drugs because pharma hasn't gotten to them yet — the FDA-approved stuff is what's been corrupted by Big Pharma.
The 'research only' label has nothing to do with safety. It's a regulatory-status designation that means the molecule has not undergone the trials FDA approval requires — typically because no commercial sponsor has reason to fund those trials. Conflating administrative labeling with safety profile inverts the actual evidence landscape.
Read the full response
31·Field-wide objection
Russian peptides like Selank, Semax, Epitalon, and Cerebrolysin have been used clinically in Russia for 20-30 years with no major safety issues — that's a long safety record.
Long clinical use under one regulatory regime is not equivalent to systematic pharmacovigilance under modern adverse-event-reporting infrastructure; the absence of published Russian adverse-event signal is consistent with both 'these molecules are safe' and 'the surveillance infrastructure that would detect signal does not match contemporary Western standards.'
Read the full response
32·On Selank
Selank is a Russian psychotropic with no Western evidence
The Russian clinical literature exists and is substantial; what is missing is independent Western RCT replication — and the right framing is parallel evidence bases that have not yet converged, not an absence of evidence.
Read the full response
33·On Semaglutide
Semaglutide makes you lose muscle
Lean-mass loss during semaglutide-induced weight loss is real and measurable, but the magnitude varies widely across studies, much of it tracks what any equivalent caloric deficit produces, and the published mitigation (adequate protein plus resistance training) consistently moves the lean-mass-to-fat-loss ratio in the right direction.
Read the full response
34·Field-wide objection
Sermorelin is safer than CJC-1295 or Tesamorelin because its sequence is closer to endogenous human GHRH — it's more natural.
Sermorelin, CJC-1295, and Tesamorelin all share the same pituitary GHRH-receptor mechanism. The difference between them is pharmacokinetic (half-life), not safety-conceptual. The naturalistic-fallacy framing treats 'closer to endogenous' as a safety axis when the actual safety data ranks Tesamorelin (the most-engineered, FDA-approved) as the best-characterized of the class.
Read the full response
35·Field-wide objection
Stacking multiple peptides multiplies the effects — five peptides at once is five times the result.
The 'stack everything' framing assumes additive or multiplicative effects across receptor systems that the actual pharmacology rarely supports. Some pairings are mechanistically complementary; many are independent; some compete or are mutually antagonistic. Stacking without attribution-aware design produces unattributable outcomes, not multiplied effects.
Read the full response
36·Field-wide objection
Subcutaneous vs intramuscular injection is just a preference — the absorption is the same in the end, and bioavailability is essentially identical regardless of route. Pick whichever hurts less.
Subcutaneous and intramuscular injection differ in absorption rate, peak concentration, time to peak, terminal half-life, and lymphatic vs vascular partitioning — these differences matter for some peptides and are negligible for others; the 'they're the same' framing flattens a real pharmacokinetic distinction.
Read the full response
37·Field-wide objection
Subdermal hormone / peptide pellets give the same effect as daily or weekly injections — they're just easier and avoid the pain of injections. Pellets are pharmacologically equivalent.
Subdermal pellets and injections produce different pharmacokinetic profiles, different patient-experience profiles, and different clinical-outcome profiles. The pellet is a depot-release formulation that produces a steady-state level very different from the peak-trough cycling of injection-based therapy — and steady-state is not always what produces the desired effect.
Read the full response
38·Field-wide objection
Subq vs IM doesn't matter — peptides are peptides; just inject wherever, they end up in the same place.
Route and injection-site technique materially affect absorption, peak concentration, side-effect profile, and the actual pharmacological signature. The 'just inject anywhere' framing is wrong for specific peptides where the published evidence and the community protocols both consistently specify route.
Read the full response
39·Field-wide objection
There's no human research on most of these peptides
The claim is partially true and the part that is true matters, but the corpus splits cleanly into peptides with substantial human RCT evidence (Tesamorelin, Semaglutide, Tirzepatide, PT-141) and peptides where the human data is genuinely thin — and the page on each peptide says which is which.
Read the full response